全球风湿病治疗市场规模、份额、趋势和成长分析报告（2026-2034）

预计类风湿性关节炎治疗市场将从 2025 年的 548.6 亿美元成长到 2034 年的 708.3 亿美元，2026 年至 2034 年的复合年增长率为 2.88%。

由于类风湿性关节炎和狼疮等自体免疫和发炎性疾病的盛行率不断上升，全球类风湿性关节炎治疗市场正在不断扩大。人口老化和早期诊断意识提升也是推动市场成长的重要因素。生物製药疗法和标靶治疗的进步改善了患者的治疗效果。医疗保健服务的普及和诊断能力的提升进一步巩固了市场地位。

关键成长要素包括生物製药和生物相似药在慢性发炎性疾病治疗的应用日益广泛。免疫学和个人化医疗领域研究投入的增加正在推动治疗方法创新。医疗费用支出的成长和有利的报销政策也在推动需求。製药公司与研究机构之间的合作正在加速产品开发和商业化进程。

展望未来，精准医疗和新型药物递送系统的进步预计将对市场产生正面影响。新兴经济体医疗基础设施的不断完善为市场提供了巨大的成长机会。持续关注延缓疾病进展和提高患者生活品质将决定未来治疗方法的发展方向。随着免疫学研究的不断创新，类风湿性关节炎治疗市场预计将持续扩张。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球类风湿性关节炎治疗市场：依药物类别划分

• 市场分析、洞察与预测
• 缓解疾病抗风湿药物（DMARDs）
• 非类固醇消炎剂（NSAIDs）
• 皮质类固醇
• 尿酸药物
• 其他的

第五章 全球类风湿性关节炎治疗市场：依适应症划分

• 市场分析、洞察与预测
• 类风湿性关节炎
• 骨关节炎
• 痛风
• 干癣性关节炎
• 僵直性脊椎炎
• 其他的

第六章 全球类风湿性关节炎治疗市场：依给药途径划分

• 市场分析、洞察与预测
• 肠外途径
• 口服给药途径
• 局部的

第七章 全球类风湿性关节炎药物市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第八章 全球风湿病治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Merck & Co. Inc
  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc
  • Genentech Inc
  • Novartis AG
  • Johnson & Johnson Innovative Medicine
  • F. Hoffmann-La Roche AG
  • Sanofi

The Rheumatology Therapeutics Market size is expected to reach USD 70.83 Billion in 2034 from USD 54.86 Billion (2025) growing at a CAGR of 2.88% during 2026-2034.

The Global Rheumatology Therapeutics Market is expanding due to the increasing prevalence of autoimmune and inflammatory disorders such as rheumatoid arthritis and lupus. Aging populations and rising awareness about early diagnosis contribute significantly to growth. Advancements in biologic therapies and targeted treatments have improved patient outcomes. Expanding healthcare access and improved diagnostic capabilities further strengthen the market.

Key drivers include growing adoption of biologics and biosimilars for managing chronic inflammatory conditions. Rising research investments in immunology and personalized medicine enhance therapeutic innovation. Increasing healthcare expenditure and supportive reimbursement policies also drive demand. Collaborations between pharmaceutical companies and research institutes accelerate product development and commercialization.

Looking forward, the market is expected to benefit from advancements in precision medicine and novel drug delivery systems. Emerging economies with improving healthcare infrastructure will offer significant growth opportunities. Continued focus on reducing disease progression and improving quality of life will shape future therapies. As innovation continues in immunology research, the rheumatology therapeutics market is poised for sustained expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Disease Modifying Anti-rheumatic Drugs (DMARDs)
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Uric Acid Drugs
• Others

By Disease Indication

• Rheumatoid Arthritis
• Osteoarthritis
• Gout
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Others

By Route of Administration

• Parenteral Route
• Oral Route
• Topical

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• Merck Co Inc, AbbVie Inc, BristolMyers Squibb Company, Pfizer Inc, Takeda Pharmaceutical Company Limited, Amgen Inc, Genentech Inc, Novartis AG, Johnson Johnson Innovative Medicine, F HoffmannLa Roche AG, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Disease Modifying Anti-rheumatic Drugs (DMARDs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Uric Acid Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Indication
• 5.2. Rheumatoid Arthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Osteoarthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Gout Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Psoriatic Arthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Ankylosing Spondylitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Parenteral Route Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Route Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Disease Indication
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Disease Indication
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Disease Indication
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Disease Indication
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Disease Indication
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL RHEUMATOLOGY THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Merck & Co. Inc
  • 10.2.2 AbbVie Inc
  • 10.2.3 Bristol-Myers Squibb Company
  • 10.2.4 Pfizer Inc
  • 10.2.5 Takeda Pharmaceutical Company Limited
  • 10.2.6 Amgen Inc
  • 10.2.7 Genentech Inc
  • 10.2.8 Novartis AG
  • 10.2.9 Johnson & Johnson Innovative Medicine
  • 10.2.10 F. Hoffmann-La Roche AG
  • 10.2.11 Sanofi